SCHEMBL4050496

SCHEMBL4050496

Fc1ccccc1-c1ccc2nc(-c3cc(C(F)(F)F)cc(C(F)(F)F)c3)oc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VSIR Q9H7M9 2/20 0.53
GPR119 Q8TDV5 5/20 0.48
HDAC6 Q9UBN7 2/20 0.45
EPHX2 P34913 1/20 0.45
HDAC3 O15379 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
ESR1 P03372 2/20 0.42
ESR2 Q92731 2/20 0.42
BACE1 P56817 1/20 0.42
PIK3R1 P27986 1/20 0.41
PIK3CA P42336 1/20 0.41
HSPD1 P10809 3/20 0.40
PTPN2 P17706 3/20 0.40
PTPN1 P18031 3/20 0.40
PTPN5 P54829 3/20 0.40
HSPE1 P61604 3/20 0.40
MAPT P10636 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4051906 0.94 VSIR (0.50) VSIRGPR119HDAC6EPHX2HDAC3
SCHEMBL4052730 0.90 VSIR (0.59) VSIRGPR119HDAC6EPHX2HDAC3
SCHEMBL4062955 0.84 VSIR (0.56) VSIRGPR119HDAC6HDAC3HDAC1
SCHEMBL4054476 0.84 VSIR (0.61) VSIRGPR119HDAC6HDAC3HDAC1
SCHEMBL4054275 0.80 VSIR (0.63) VSIRGPR119HDAC6HDAC3HDAC1
SCHEMBL13608507 0.79 VSIR (0.59) VSIRGPR119HDAC6HDAC3HDAC1
SCHEMBL4057762 0.78 BACE1 (0.46) VSIREPHX2ESR1ESR2BACE1
SCHEMBL4051991 0.78 VSIR (0.56) VSIRGPR119HDAC6HDAC3HDAC1
SCHEMBL4057847 0.78 VSIR (0.56) VSIRGPR119HDAC6HDAC3HDAC1
SCHEMBL4054281 0.78 NPC1 (0.55) VSIRGPR119HDAC6HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B VSIR 4618/4885GPR119 1677/4885HDAC6 698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.